title: [Identification and management of hereditary breast-ovarian cancers (2004 update)].
abstract: BACKGROUND
  Since the last recommendations, up to 2500 new references had been published on that topic.
  
  
  METHODS
  On the behalf of the health Minister, the Ad Hoc Committee consisted of 13 experts carried out a first version revisited by five additional experts who critically analyzed the first version of the report.
  
  
  METHODS
  Breast and ovarian cancer seem to be associated with fewer deleterious mutations of BRCA1 and BRCA2 than previously thought. The screening of ovarian cancer is still not an attractive option while in contrast MRI may be soon for these young women with dense breast, the recommended option for breast cancer screening. The effectiveness of prophylactic surgeries is now well established. French position is to favor such surgeries with regard to a quality of life in line with the expected benefit, and providing precise and standardized process described in the recommendation.
  
  
  CONCLUSIONS
  Due to methodological flaws, the low power and a short follow-up of the surveys, this statement cannot however aspire to a high stability.
authors.affiliation: Département d'oncogénétique, institut Paoli-Calmettes, Marseille, France. eisinger@marseille.inserm.fr
authors.forename: F
authors.initials: F
authors.lastname: Eisinger
authors.forename: B
authors.initials: B
authors.lastname: Bressac
authors.forename: D
authors.initials: D
authors.lastname: Castaigne
authors.forename: P-H
authors.initials: PH
authors.lastname: Cottu
authors.forename: J
authors.initials: J
authors.lastname: Lansac
authors.forename: J-P
authors.initials: JP
authors.lastname: Lefranc
authors.forename: A
authors.initials: A
authors.lastname: Lesur
authors.forename: C
authors.initials: C
authors.lastname: Noguès
authors.forename: J
authors.initials: J
authors.lastname: Pierret
authors.forename: S
authors.initials: S
authors.lastname: Puy-Pernias
authors.forename: H
authors.initials: H
authors.lastname: Sobol
authors.forename: A
authors.initials: A
authors.lastname: Tardivon
authors.forename: H
authors.initials: H
authors.lastname: Tristant
authors.forename: R
authors.initials: R
authors.lastname: Villet
mesh_terms: D001943:Breast Neoplasms / Q000453:epidemiology / Q000235:genetics* / Q000601:surgery / Q000628:therapy; D003219:Confidentiality; D005260:Female; D005602:France / Q000453:epidemiology; D019398:Genes, BRCA1; D024522:Genes, BRCA2; D005838:Genotype; D006801:Humans; D008408:Mastectomy; D010051:Ovarian Neoplasms / Q000453:epidemiology / Q000235:genetics* / Q000628:therapy; D010641:Phenotype; D010817:Physician-Patient Relations